CAR, CAR., CAR.NK92 cells, CCL3, CD19, CD19.CAR.NK92, CD20, FASL, IFN, IL10, LDH, NK cells, NK92, SUDHL4, anti, anti-CD19 chimeric antigen receptor, anti-CD20, anti-CD20 resistant cell lines, anti-CD20 resistant cells, cell lines, flow, flow-sorted lymphoma cells, genes, granzymes, human, large B-cell, large B-cell, follicular, and Burkitt lymphoma, lymphoma, lymphoma cell lines, lymphoma cells, mTOR, natural killer, non-hodgkin lymphoma, obinutuzumab, patient, patient-derived cells, resistant cells, rituximab, rituximab- and obinutuzumab-resistant cells